Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | See Remarks | December 28, 2020 | December 30, 2020 |
| Damora Therapeutics, Inc.DMRA · Entity 4602 | Director | March 23, 2026 | March 25, 2026 |
| Oruka Therapeutics, Inc.ORKA · Entity 3781 | Director | June 02, 2025 | June 03, 2025 |
| Spyre Therapeutics, Inc.SYRE · Entity 2649 | Director · Chief Executive Officer | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Pharma, Inc.
Report date December 28, 2020 · Filed December 30, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,568 |
Ending reported balance
After 2020-12-28 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2020-12-28 · Exercise / conversion · Acquired 7,500 · Balance 20,068 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. Row 2 · 2020-12-28 · Exercise / conversion · Acquired 6,000 · Balance 26,068 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. Row 3 · 2020-12-28 · Exercise / conversion · Acquired 6,000 · Balance 32,068 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. Row 4 · 2020-12-28 · Sale · Disposed 10,937 · Balance 21,131 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. F2: Represents the weighted average sale price of the shares sold from $68.73 to $69.725 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3. Row 5 · 2020-12-28 · Sale · Disposed 8,563 · Balance 12,568 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. F3: Represents the weighted average sale price of the shares sold from $69.73 to $70.52 per share. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2029-06-26 | Direct | 255,500 |
Reported balance
After 2020-12-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-12-28 · Exercise / conversion · Disposed 7,500 · Balance 255,500 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. F4: The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.34 · Expires 2029-07-14 | Direct | 31,766 |
Reported balance
After 2020-12-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-12-28 · Exercise / conversion · Disposed 6,000 · Balance 31,766 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.16 · Expires 2029-05-23 | Direct | 56,042 |
Reported balance
After 2020-12-28 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-12-28 · Exercise / conversion · Disposed 6,000 · Balance 56,042 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020.
F2: Represents the weighted average sale price of the shares sold from $68.73 to $69.725 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3.
F3: Represents the weighted average sale price of the shares sold from $69.73 to $70.52 per share.
F4: The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
Damora Therapeutics, Inc.
Report date March 23, 2026 · Filed March 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.05 · Expires 2036-03-23 | Direct | 37,313 |
Reported balance
After 2026-03-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-23 · Grant · Acquired 37,313 · Balance 37,313 F1: This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through March 23, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through March 23, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Oruka Therapeutics, Inc.
Report date June 02, 2025 · Filed June 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.77 · Expires 2035-06-01 | Direct | 17,500 |
Reported balance
After 2025-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-02 · Grant · Acquired 17,500 · Balance 17,500 F1: The option vests as to 1/12 of the underlying shares monthly from June 2, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 1/12 of the underlying shares monthly from June 2, 2025.
Spyre Therapeutics, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 537,540 |
Last balance in matching sequence
After 2026-10-01 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rowsRow 1 · 2026-10-01 · Sale · Disposed 600 · Balance 551,940 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. F3: Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Row 2 · 2026-10-01 · Sale · Disposed 2,683 · Balance 549,257 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.80 to $90.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3: Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Row 3 · 2026-10-01 · Sale · Disposed 2,638 · Balance 546,619 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F5: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.85 to $91.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3: Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Row 4 · 2026-10-01 · Sale · Disposed 3,989 · Balance 542,630 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F6: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.87 to $92.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3: Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Row 5 · 2026-10-01 · Sale · Disposed 4,990 · Balance 537,640 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F7: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.89 to $93.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3: Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Row 6 · 2026-10-01 · Sale · Disposed 100 · Balance 537,540 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F3: Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
F3: Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.
F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.80 to $90.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F5: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.85 to $91.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F6: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.87 to $92.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F7: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.89 to $93.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Eidos Therapeutics, Inc.
Report date January 26, 2021 · Filed January 28, 2021
Section 16 reporting ended · disclosed 2021-01-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-01-26 transaction · row 1
1 source rowRow 1 · 2021-01-26 · Other · Disposed 50,699 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). At the Effective Time, each share of Issuer common stock that was outstanding and held by the Reporting Person immediately prior to the Effective Time was cancelled and automatically converted into 1.85 shares of Parent common stock. F2: Includes 78 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2020. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2028-06-20 | Direct | 0 |
Reported balance
After 2021-01-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-01-26 · Disposition to issuer · Disposed 9,469 · Balance 0 F3: The option vests over four years after June 18, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.20 · Expires 2028-11-05 | Direct | 0 |
Reported balance
After 2021-01-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-01-26 · Disposition to issuer · Disposed 53,157 · Balance 0 F4: The option vests over four years after November 5, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). At the Effective Time, each share of Issuer common stock that was outstanding and held by the Reporting Person immediately prior to the Effective Time was cancelled and automatically converted into 1.85 shares of Parent common stock.
F2: Includes 78 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2020.
F3: The option vests over four years after June 18, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time.
F4: The option vests over four years after November 5, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 01:29 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 100 | $93.91 | $9,391.00 |
DisclosureSEC source: 0001636282-26-000118 · wk-form4_1790990994.xml · nonDerivative · entry 6 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 537,540 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F3 · balance_after: Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:29 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 4,990 | $93.37 | $465,916.30 |
DisclosureSEC source: 0001636282-26-000118 · wk-form4_1790990994.xml · nonDerivative · entry 5 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 537,640 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F7 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.89 to $93.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:29 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 3,989 | $92.31 | $368,224.59 |
DisclosureSEC source: 0001636282-26-000118 · wk-form4_1790990994.xml · nonDerivative · entry 4 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 542,630 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F6 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.87 to $92.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:29 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 2,638 | $91.49 | $241,350.62 |
DisclosureSEC source: 0001636282-26-000118 · wk-form4_1790990994.xml · nonDerivative · entry 3 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 546,619 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.85 to $91.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:29 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 2,683 | $90.10 | $241,738.30 |
DisclosureSEC source: 0001636282-26-000118 · wk-form4_1790990994.xml · nonDerivative · entry 2 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 549,257 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.80 to $90.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:29 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 600 | $89.14 | $53,484.00 |
DisclosureSEC source: 0001636282-26-000118 · wk-form4_1790990994.xml · nonDerivative · entry 1 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 551,940 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| September 01, 2026 Filed Sep 4, 2026 01:33 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 400 | $89.07 | $35,628.00 |
DisclosureSEC source: 0001636282-26-000107 · wk-form4_1788485583.xml · nonDerivative · entry 4 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 552,540 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F6 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.69 to $89.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 43,593 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| September 01, 2026 Filed Sep 4, 2026 01:33 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 3,700 | $88.06 | $325,822.00 |
DisclosureSEC source: 0001636282-26-000107 · wk-form4_1788485583.xml · nonDerivative · entry 3 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 552,940 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.68 to $88.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 43,593 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| September 01, 2026 Filed Sep 4, 2026 01:33 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 8,400 | $87.15 | $732,060.00 |
DisclosureSEC source: 0001636282-26-000107 · wk-form4_1788485583.xml · nonDerivative · entry 2 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 556,640 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.67 to $87.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 43,593 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| September 01, 2026 Filed Sep 4, 2026 01:33 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 2,500 | $86.36 | $215,900.00 |
DisclosureSEC source: 0001636282-26-000107 · wk-form4_1788485583.xml · nonDerivative · entry 1 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 565,040 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.67 to $86.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 43,593 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| August 03, 2026 Filed Aug 6, 2026 01:31 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 16 | $97.46 | $1,559.36 |
DisclosureSEC source: 0001636282-26-000099 · wk-form4_1785979866.xml · nonDerivative · entry 5 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 567,540 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F7 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.46 to $97.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| August 03, 2026 Filed Aug 6, 2026 01:31 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 1,392 | $96.82 | $134,773.44 |
DisclosureSEC source: 0001636282-26-000099 · wk-form4_1785979866.xml · nonDerivative · entry 4 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 567,556 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F6 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $96.45 to $97.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| August 03, 2026 Filed Aug 6, 2026 01:31 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 5,635 | $95.93 | $540,565.55 |
DisclosureSEC source: 0001636282-26-000099 · wk-form4_1785979866.xml · nonDerivative · entry 3 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 568,948 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $95.45 to $96.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| August 03, 2026 Filed Aug 6, 2026 01:31 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 7,157 | $95.10 | $680,630.70 |
DisclosureSEC source: 0001636282-26-000099 · wk-form4_1785979866.xml · nonDerivative · entry 2 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 574,583 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $94.44 to $95.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| August 03, 2026 Filed Aug 6, 2026 01:31 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 800 | $93.97 | $75,176.00 |
DisclosureSEC source: 0001636282-26-000099 · wk-form4_1785979866.xml · nonDerivative · entry 1 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 581,740 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.42 to $94.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| July 01, 2026 Filed Jul 3, 2026 01:32 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 590 | $88.91 | $52,456.90 |
DisclosureSEC source: 0001636282-26-000086 · wk-form4_1783042321.xml · nonDerivative · entry 3 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 582,540 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.86 to $88.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 72,623 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| July 01, 2026 Filed Jul 3, 2026 01:32 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 4,234 | $88.12 | $373,100.08 |
DisclosureSEC source: 0001636282-26-000086 · wk-form4_1783042321.xml · nonDerivative · entry 2 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 583,130 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.82 to $88.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 72,623 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| July 01, 2026 Filed Jul 3, 2026 01:32 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 10,176 | $87.44 | $889,789.44 |
DisclosureSEC source: 0001636282-26-000086 · wk-form4_1783042321.xml · nonDerivative · entry 1 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 587,364 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.82 to $87.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 72,623 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 01, 2026 Filed Jun 4, 2026 01:31 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 3,294 | $71.38 | $235,125.72 |
DisclosureSEC source: 0001636282-26-000077 · wk-form4_1780536669.xml · nonDerivative · entry 3 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 597,540 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.97 to $71.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 87,138 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 01, 2026 Filed Jun 4, 2026 01:31 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 8,149 | $70.50 | $574,504.50 |
DisclosureSEC source: 0001636282-26-000077 · wk-form4_1780536669.xml · nonDerivative · entry 2 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 600,834 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.96 to $70.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 87,138 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 01, 2026 Filed Jun 4, 2026 01:31 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 3,557 | $69.40 | $246,855.80 |
DisclosureSEC source: 0001636282-26-000077 · wk-form4_1780536669.xml · nonDerivative · entry 1 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 608,983 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.96 to $69.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 87,138 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| May 01, 2026 Filed May 2, 2026 01:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 300 | $74.96 | $22,488.00 |
DisclosureSEC source: 0001758363-26-000009 · wk-form4_1777685648.xml · nonDerivative · entry 6 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 612,540 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F8 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.95 to $74.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 101,653 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| May 01, 2026 Filed May 2, 2026 01:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 1,700 | $74.23 | $126,191.00 |
DisclosureSEC source: 0001758363-26-000009 · wk-form4_1777685648.xml · nonDerivative · entry 5 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 612,840 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F7 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.95 to $74.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 101,653 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| May 01, 2026 Filed May 2, 2026 01:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 3,100 | $73.14 | $226,734.00 |
DisclosureSEC source: 0001758363-26-000009 · wk-form4_1777685648.xml · nonDerivative · entry 4 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 614,540 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F6 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.75 to $73.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 101,653 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| May 01, 2026 Filed May 2, 2026 01:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 1,000 | $71.76 | $71,760.00 |
DisclosureSEC source: 0001758363-26-000009 · wk-form4_1777685648.xml · nonDerivative · entry 3 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 617,640 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.41 to $72.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 101,653 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| May 01, 2026 Filed May 2, 2026 01:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 3,600 | $70.77 | $254,772.00 |
DisclosureSEC source: 0001758363-26-000009 · wk-form4_1777685648.xml · nonDerivative · entry 2 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 618,640 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.30 to $71.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 101,653 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| May 01, 2026 Filed May 2, 2026 01:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 5,300 | $69.54 | $368,562.00 |
DisclosureSEC source: 0001758363-26-000009 · wk-form4_1777685648.xml · nonDerivative · entry 1 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 622,240 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.25 to $70.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 101,653 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| April 01, 2026 Filed Apr 4, 2026 01:30 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 2,656 | $49.92 | $132,587.52 |
DisclosureSEC source: 0001758363-26-000007 · wk-form4_1775266241.xml · nonDerivative · entry 2 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 627,540 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.64 to $50.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 116,168 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| April 01, 2026 Filed Apr 4, 2026 01:30 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 12,344 | $49.20 | $607,324.80 |
DisclosureSEC source: 0001758363-26-000007 · wk-form4_1775266241.xml · nonDerivative · entry 1 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 630,196 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.64 to $49.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 116,168 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 22:08 UTC | Damora Therapeutics, Inc. DMRA · Entity 4602 | GrantStock Option (right to buy) · Derivative | 37,313 | $0.00 Strike: $23.05 | $0.00 |
DisclosureSEC source: 0001193125-26-124483 · ownership.xml · derivative · entry 1 Turtle Cameron · CIK 0001758363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,313 Underlying: Common Stock · 37,313 shares Expires 2036-03-23 F1 · derivative.exercise_date: This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through March 23, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 02:31 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 9,100 | $42.49 | $386,659.00 |
DisclosureSEC source: 0001636282-26-000026 · wk-form4_1772591487.xml · nonDerivative · entry 2 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 642,540 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.23 to $42.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 130,683 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 02:31 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 5,900 | $41.73 | $246,207.00 |
DisclosureSEC source: 0001636282-26-000026 · wk-form4_1772591487.xml · nonDerivative · entry 1 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 651,640 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.23 to $42.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 130,683 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 02:33 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 14,043 | $32.87 | $461,593.41 |
DisclosureSEC source: 0001758363-26-000005 · wk-form4_1770258815.xml · nonDerivative · entry 2 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 657,540 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.48 to $33.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 145,198 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 02:33 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 957 | $31.82 | $30,451.74 |
DisclosureSEC source: 0001758363-26-000005 · wk-form4_1770258815.xml · nonDerivative · entry 1 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 671,583 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.42 to $32.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 145,198 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date. F4 · balance_after: Includes 633 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on August 15, 2024. Read SEC document |
| January 09, 2026 Filed Jan 14, 2026 02:27 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | GrantStock Option (Right to Buy) · Derivative | 528,000 | $0.00 Strike: $30.61 | $0.00 |
DisclosureSEC source: 0001636282-26-000003 · wk-form4_1768357625.xml · derivative · entry 1 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 528,000 Underlying: Common Stock · 528,000 shares Expires 2036-01-09 F1 · derivative.exercise_date: This option represents a right to purchase 528,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 02:36 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 100 | $32.39 | $3,239.00 |
DisclosureSEC source: 0001758363-26-000002 · wk-form4_1767753388.xml · nonDerivative · entry 3 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 671,907 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.34 to $32.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 159,713 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 02:36 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 2,191 | $31.79 | $69,651.89 |
DisclosureSEC source: 0001758363-26-000002 · wk-form4_1767753388.xml · nonDerivative · entry 2 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 672,007 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.29 to $32.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 159,713 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 02:36 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 12,709 | $30.47 | $387,243.23 |
DisclosureSEC source: 0001758363-26-000002 · wk-form4_1767753388.xml · nonDerivative · entry 1 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 674,198 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.20 to $31.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 159,713 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 02:52 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 4,005 | $29.83 | $119,469.15 |
DisclosureSEC source: 0001758363-25-000003 · wk-form4_1764816738.xml · nonDerivative · entry 2 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 686,907 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.47 to $30.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 174,228 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 02:52 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 10,995 | $28.73 | $315,886.35 |
DisclosureSEC source: 0001758363-25-000003 · wk-form4_1764816738.xml · nonDerivative · entry 1 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 690,912 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.45 to $29.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 174,228 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| November 03, 2025 Filed Nov 6, 2025 02:15 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 16,845 | $23.66 | $398,552.70 |
DisclosureSEC source: 0001636282-25-000106 · wk-form4_1762395302.xml · nonDerivative · entry 2 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 701,907 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.51 to $24.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 188,743 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| November 03, 2025 Filed Nov 6, 2025 02:15 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 28,155 | $23.13 | $651,225.15 |
DisclosureSEC source: 0001636282-25-000106 · wk-form4_1762395302.xml · nonDerivative · entry 1 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 718,752 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.51 to $23.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 188,743 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:13 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $11.77 | $0.00 |
DisclosureSEC source: 0001062993-25-010824 · form4.xml · derivative · entry 1 Turtle Cameron · CIK 0001758363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2035-06-01 F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from June 2, 2025. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:35 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | GrantStock Option (Right to Buy) · Derivative | 370,000 | $0.00 Strike: $21.66 | $0.00 |
DisclosureSEC source: 0001636282-25-000008 · wk-form4_1737149707.xml · derivative · entry 1 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 370,000 Underlying: Common Stock · 370,000 shares Expires 2035-01-15 F1 · derivative.exercise_date: This option represents a right to purchase 370,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date. Read SEC document |
| February 15, 2024 Filed Feb 21, 2024 02:21 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | GrantCommon Stock | 400 | $9.82 | $3,928.00 |
DisclosureSEC source: 0000950170-24-017494 · ownership.xml · nonDerivative · entry 1 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 746,907 F1 · kind: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). F2 · balance_after: Includes 493,558 shares of common stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| February 01, 2024 Filed Feb 3, 2024 01:31 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | GrantStock Option (Right to Buy) · Derivative | 277,750 | $0.00 Strike: $25.86 | $0.00 |
DisclosureSEC source: 0000950170-24-010904 · ownership.xml · derivative · entry 1 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 277,750 Underlying: Common Stock · 277,750 shares Expires 2034-02-01 F1 · derivative.exercise_date: This option represents a right to purchase 277,750 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date. Read SEC document |
| November 24, 2023 Filed Nov 27, 2023 21:25 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | ConversionSeries A Preferred Stock · Derivative | 18,086 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-066131 · ownership.xml · derivative · entry 3 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 723,440 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain limitations. F1 · kind: Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain limitations. F1 · derivative.exercise_date: Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain limitations. F1 · derivative.expiration_date: Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain limitations. Read SEC document |
| November 24, 2023 Filed Nov 27, 2023 21:25 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | ConversionCommon Stock | 723,440 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-066131 · ownership.xml · nonDerivative · entry 1 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 746,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain limitations. F2 · shares: Includes 506,440 shares of common stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date. F3 · balance_after: Includes 522,588 shares of common stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| November 22, 2023 Filed Nov 27, 2023 21:25 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantStock Option (Right to Buy) · Derivative | 374,000 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0000950170-23-066131 · ownership.xml · derivative · entry 2 Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 374,000 Underlying: Common Stock · 374,000 shares Expires 2033-11-22 F4 · derivative.exercise_date: This option represents a right to purchase 374,000 shares of the Issuer's common stock, one quarter of which will vest and become exercisable on November 22, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer at each vesting date. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 19:15 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Disposition to issuerStock Option (Right to Buy) · Derivative | 53,157 | Not disclosed Strike: $13.20 | Not disclosed |
DisclosureSEC source: 0000899243-21-003649 · doc4.xml · derivative · entry 3 Turtle Cameron · CIK 0001758363 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 53,157 shares Expires 2028-11-05 F4 · price: The option vests over four years after November 5, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time. F4 · derivative.exercise_date: The option vests over four years after November 5, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.